Press Releases

Press Releases

or

September 11, 2014
BEIJING, China, September 11, 2014 — BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company’s collaboration with Merck Serono, the biopharmaceutical division
August 27, 2014
Jason Yang, M.D., Ph.D., appointed Senior Vice President of Clinical Development & Operations and Wendy Yan, Senior Vice President of Regulatory Affairs New additions strengthen BeiGene leadership team and bring deep global clinical development and regulatory expertise BEIJING, China, August 27,
August 26, 2014
Wholly-owned BTK inhibitor will be tested in dose escalation cohorts in indolent B-cell malignancies to establish single-agent properties and preliminary anti-tumor activity Third oncology candidate to enter clinic within last 9 months BEIJING, China—August 26, 2014—BeiGene (Beijing), Co., Ltd., an
July 7, 2014
PARP inhibitor will be tested in disease-specific dose escalation cohorts to establish single-agent properties and preliminary anti-tumor activity BEIJING, China—July 7, 2014— BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune- oncology
March 18, 2014
CNCBD (China National Center for Biotechnology Development) Director Huang Jing visited BeiGene on March 13. About China National Center for Biotechnology Development China National Center for Biotechnology Development (abbreviated ass CNCBD in the following d description) is an organization
March 10, 2014
Beijing, China, March 10, 2014 — BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the upcoming presentation of two posters by company scientists and advisors at the American Association for Cancer Research
March 3, 2014
Eminent cancer researcher in immune-oncology and lymphoma to further strengthen company capabilities BEIJING, China, March 3, 2014 — BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the addition of Dr.